Literature DB >> 16884772

Molecular basis for decreased folylpoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line.

Guy J Leclerc1, Teresa A York, Tingting Hsieh-Kinser, Julio C Barredo.   

Abstract

A CCRF-CEM mutant, CEM-p, has been shown to exhibit resistance to methotrexate due to decreased methotrexate polyglutamate accumulation. To ascertain the mechanism(s) responsible for this phenotype, we analyzed FPGS and SLC19A1 mRNA expression, examined FPGS promoter activity, and determined nucleotide sequence of the FPGS promoter and full length cDNA from CCRF-CEM and CEM-p cells. We identified in FPGS from CEM-p cells three amino acid substitutions that altered the ATP binding P-loop, glutamate/folate binding, and a conserved domain located at the carboxyl-terminal. Our data demonstrated for the first time the importance of the highly conserved domain (VTGSLHLVGGV) located at the carboxyl-terminal for FPGS activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884772     DOI: 10.1016/j.leukres.2006.06.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

Authors:  Guy J Leclerc; Christopher Sanderson; Stephen Hunger; Meenakshi Devidas; Julio C Barredo
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

2.  Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.

Authors:  Daniel Nowak; Natalia L M Liem; Maximilian Mossner; Marion Klaumünzer; Rachael A Papa; Verena Nowak; Johann C Jann; Tadayuki Akagi; Norihiko Kawamata; Ryoko Okamoto; Nils H Thoennissen; Motohiro Kato; Masashi Sanada; Wolf-Karsten Hofmann; Seishi Ogawa; Glenn M Marshall; Richard B Lock; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2014-10-29       Impact factor: 3.084

3.  Effect of the Polymorphism of Folylpolyglutamate Synthetase on Treatment of High-Dose Methotrexate in Pediatric Patients with Acute Lymphocytic Leukemia.

Authors:  Zhen Huang; Hong-Fei Tong; Yuan Li; Jiang-Chao Qian; Ju-Xiang Wang; Zhe Wang; Ji-Chen Ruan
Journal:  Med Sci Monit       Date:  2016-12-17

4.  Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.

Authors:  Shuhua Zheng; Gilles M Leclerc; Bin Li; Ronan T Swords; Julio C Barredo
Journal:  Oncotarget       Date:  2017-12-31

5.  Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

Authors:  E Izbicka; A Diaz; R Streeper; M Wick; D Campos; R Steffen; M Saunders
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

6.  Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia.

Authors:  Shachar Raz; Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2014-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.